Business Overview: Immunome, Inc. (NASDAQ: IMNM)

---

Executive Summary

Immunome, Inc. is a biotechnology company developing first-in-class and best-in-class targeted oncology therapies, with a particular focus on antibody-drug conjugates (ADCs) against novel, underexplored tumor targets. The company has screened more than 1,000 potential targets to build a pipeline of three clinical and three preclinical assets.

Its nearest-term value driver is varegacestat, an oral gamma secretase inhibitor for desmoid tumors, which reported positive Phase 3 topline results (RINGSIDE trial) in December 2025, with an NDA submission expected in Q2 2026 — putting Immunome on the cusp of its first potential FDA approval and commercial launch.

---

1. Core Business Model & How They Work

[ Target-Driven Discovery (1,000+ targets screened) ] ➡️ [ Proprietary ADC Payload (HC74) + Undisclosed Linkers ] ➡️ [ Clinical Development ] ➡️ [ NDA/BLA Filing ] ➡️ [ Focused U.S. Commercialization + Selective Ex-U.S. Partnering ]

Key Operational Drivers

1. Target-Driven Discovery: Rather than pursuing already-crowded targets, Immunome screens for novel or underexplored targets with no approved ADCs, yielding more than 40 targets evaluated in vitro and 15+ in vivo from over 1,000 screened.
2. Proprietary Payload Technology: Its HC74 topoisomerase 1 (TOP1) inhibitor payload is designed to overcome efflux-based drug resistance and improve "bystander" killing of neighboring tumor cells, with preclinical data the company says compare favorably to deruxtecan (DXd), the payload behind several approved ADCs.
3. Business Development as a Growth Lever: Immunome has aggressively in-licensed and acquired assets — varegacestat via the 2024 Ayala acquisition, additional programs via Zentalis licensing and asset purchases, and a Bristol Myers Squibb (BMS) license amendment — rather than relying solely on internal discovery.
4. Retained Commercial Rights: The company holds global commercial rights to varegacestat and plans a focused internal U.S. commercial organization, while flexibly retaining or partnering ex-U.S. rights.
5. Outsourced Manufacturing: Relies on third-party manufacturers for all clinical and commercial supply.

---

2. Business Segments

Immunome operates as a single integrated oncology biopharmaceutical business and does not report discrete segments; its activity is best understood program-by-program.

---

3. Product Portfolio

---

4. Competitive Landscape

For varegacestat, the direct competitor is SpringWorks Therapeutics (now part of Merck KGaA), whose nirogacestat (OGSIVEO) was FDA-approved for desmoid tumors in November 2023 — meaning Immunome would be a fast-follower rather than first-to-market in this indication, competing on differentiated efficacy/safety data. For IM-1021, competitors include Merck's zilovertamab vedotin (Phase 3) and CStone's CS5001. For IM-3050, competitors include Novartis, Ratio Therapeutics, Perspective Therapeutics, and Sinotau in the radioligand therapy space. More broadly, Immunome competes with much larger pharmaceutical companies — AbbVie (via its ImmunoGen acquisition), AstraZeneca, and Pfizer (via its Seagen acquisition) — in the broader ADC and targeted oncology market.

---

5. Strategic Strengths & Risks

Strengths

• Near-Term Commercial Catalyst: Positive Phase 3 RINGSIDE data for varegacestat, with an NDA expected in Q2 2026, gives Immunome a credible, near-dated path to its first approved product.
• Differentiated ADC Payload: The HC74 TOP1 payload's claimed resistance-overcoming and bystander-effect properties, if validated clinically, could meaningfully differentiate IM-1021 and future ADC candidates.
• Disciplined Business Development: A track record of successfully in-licensing/acquiring de-risked or partially de-risked assets (Ayala, Zentalis, BMS) rather than relying solely on slower internal discovery.
• Multiple Shots on Goal: Three clinical and three preclinical assets across different modalities (small molecule, ADC, radioligand) diversify the company's risk profile beyond a single mechanism.

Risks

• Fast-Follower Position in Desmoid Tumors: Varegacestat would launch into a market where SpringWorks/Merck KGaA's nirogacestat is already established, requiring real differentiation to win share.
• Large, Well-Funded Competitors: AbbVie, AstraZeneca, Pfizer, Merck, and Novartis all have substantially greater resources across the indications Immunome is pursuing.
• Business-Development-Heavy Model Carries Integration/Milestone Risk: Multiple stacked license/acquisition obligations (Ayala, Zentalis, BMS, Purdue) create ongoing milestone and royalty payment obligations that could total well over $150 million if programs succeed.
• Early-Stage Pipeline Depth: Beyond varegacestat, IM-1021 and IM-3050 are still in Phase 1, and the three preclinical ADCs remain pre-IND — meaningful execution risk remains across the rest of the portfolio.

---

6. Financial Overview

---

7. Summary Conclusion

Immunome has transformed itself through aggressive, disciplined business development into a company with a credible near-term approval catalyst (varegacestat) and a differentiated proprietary ADC payload technology (HC74) underpinning a multi-asset pipeline. Its moat is still emergent rather than established — varegacestat will compete as a fast-follower against an already-approved rival, and the ADC/radioligand pipeline remains early-stage — but the combination of a near-dated regulatory catalyst, genuine technical differentiation in its payload chemistry, and multiple diversified shots on goal gives Immunome a more de-risked profile than a typical single-asset clinical-stage biotech.